Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease

Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease

Soluble amyloid-beta oligomers (Aβo) start to accumulate in the human brain one to two decades before any clinical symptoms of Alzheimer's disease (AD) and are implicated in synapse loss, one of the best predictors of memory decline that characterize the illness. Cognitive impairment in AD was...

Full description

Bibliographic Details
Main Authors:	Audrey Hector, Jonathan Brouillette
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-01-01
Series:	Frontiers in Molecular Neuroscience
Subjects:	amyloid-beta oligomers hyperactivity neurodegeneration memory epileptiform activity gamma oscillations
Online Access:	https://www.frontiersin.org/articles/10.3389/fnmol.2020.600084/full

Similar Items

Doxycycline for Alzheimer’s Disease: Fighting β-Amyloid Oligomers and Neuroinflammation
by: Claudia Balducci, et al.
Published: (2019-07-01)

Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
by: Barbara Mroczko, et al.
Published: (2018-06-01)

Amyloid-β Oligomers Unveil a Novel Primate Model of Sporadic Alzheimer’s Disease
by: Joseph eJebelli, et al.
Published: (2015-03-01)

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression
by: Martin Tolar, et al.
Published: (2021-06-01)

Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation
by: Woo Shik Shin, et al.
Published: (2019-10-01)

Challenges in understanding the structure/activity relationship of Aβ oligomers
by: Albert W. Pilkington IV, et al.
Published: (2019-01-01)

β-amyloid oligomers in aging and Alzheimer's disease
by: Kathleen R. Zahs, et al.
Published: (2013-07-01)

The Toxicity and Polymorphism of β-Amyloid Oligomers
by: Ya-ru Huang, et al.
Published: (2020-06-01)

Stabilization of a Membrane-Associated Amyloid-β Oligomer for Its Validation in Alzheimer's Disease
by: Montserrat Serra-Batiste, et al.
Published: (2018-04-01)

Amyloid Prefibrillar Oligomers: The Surprising Commonalities in Their Structure and Activity
by: Marco Diociaiuti, et al.
Published: (2021-06-01)

Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s disease
by: Xue Meng, et al.
Published: (2019-10-01)

Soluble amyloid-b oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease
by: Sergio T. Ferreira, et al.
Published: (2015-05-01)

Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease
by: David L. Brody, et al.
Published: (2017-08-01)

A hydrogel biosensor for high selective and sensitive detection of amyloid-beta oligomers
by: Sun LP, et al.
Published: (2018-02-01)

Probing the Occurrence of Soluble Oligomers through Amyloid Aggregation Scaling Laws
by: Alexandra Silva, et al.
Published: (2018-10-01)

Tau as a mediator of neurotoxicity associated to cerebral amyloid angiopathy
by: Yingjian You, et al.
Published: (2019-02-01)

Soluble Aβ oligomers impair hippocampal LTP by disrupting glutamatergic/GABAergic balance
by: Ming Lei, et al.
Published: (2016-01-01)

Cellular Prion Protein as a Receptor of Toxic Amyloid-β42 Oligomers Is Important for Alzheimer’s Disease
by: Yuan Zhang, et al.
Published: (2019-07-01)

Monomeric amyloid-β reduced amyloid-β oligomer-induced synapse damage in neuronal cultures
by: Clive Bate, et al.
Published: (2018-03-01)

Taxifolin inhibits amyloid-β oligomer formation and fully restores vascular integrity and memory in cerebral amyloid angiopathy
by: Satoshi Saito, et al.
Published: (2017-04-01)

Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer’s disease model
by: Fernando Goñi, et al.
Published: (2018-01-01)

Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer’s Pathogenesis
by: Botond Penke, et al.
Published: (2020-04-01)

Different Amyloid-β Self-Assemblies Have Distinct Effects on Intracellular Tau Aggregation
by: Woo Shik Shin, et al.
Published: (2019-11-01)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
by: Martin Tolar, et al.
Published: (2020-08-01)

A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles
by: Xing Y, et al.
Published: (2017-04-01)

Taxifolin inhibits amyloid-β oligomer formation and fully restores vascular integrity and memory in cerebral amyloid angiopathy
by: Saito, Satoshi
Published: (2017)

Activated Bone Marrow-Derived Macrophages Eradicate Alzheimer's-Related Aβ42 Oligomers and Protect Synapses
by: Songlin Li, et al.
Published: (2020-01-01)

Label-free vibrational imaging of different Aβ plaque types in Alzheimer’s disease reveals sequential events in plaque development
by: Dominik Röhr, et al.
Published: (2020-12-01)

Toxic species in amyloid disorders: Oligomers or mature fibrils
by: Meenakshi Verma, et al.
Published: (2015-01-01)

Optogenetic activation of parvalbumin and somatostatin interneurons selectively restores theta-nested gamma oscillations and oscillation-induced spike timing-dependent long-term potentiation impaired by amyloid β oligomers
by: Kyerl Park, et al.
Published: (2020-01-01)

Intracellular accumulation of amyloid-beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease
by: Thomas A Bayer
Published: (2010-03-01)

Assessing the Effects of Acute Amyloid β Oligomer Exposure in the Rat
by: Ryan S. Wong, et al.
Published: (2016-08-01)

Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer’s Disease
by: Tapan Behl, et al.
Published: (2020-10-01)

Glycines from the APP GXXXG/GXXXA transmembrane motifs promote formation of pathogenic Aβ oligomers in cells
by: Marie eDecock, et al.
Published: (2016-05-01)

Single Molecule Characterization of Amyloid Oligomers
by: Jie Yang, et al.
Published: (2021-02-01)

Targeting cytotoxic species in amyloid diseases
by: Lindhagen Persson, Malin
Published: (2012)

Removal of Aβ Oligomers from the Blood: A Potential Therapeutic System for Alzheimer’s Disease
by: Saito Y, et al.
Published: (2020-03-01)

The Toxicity of Amyloid ß Oligomers
by: Lock Yue Chew, et al.
Published: (2012-06-01)

Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer’s disease
by: Shaomin Li, et al.
Published: (2018-11-01)

Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway
by: Catherine Malaplate-Armand, et al.
Published: (2006-07-01)

Cannot write session to /tmp/vufind_sessions/sess_igkmlsf8hk4v220vf6tb3vsb09